HansBiomed Past Earnings Performance
Past criteria checks 0/6
HansBiomed's earnings have been declining at an average annual rate of -34.8%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
-34.8%
Earnings growth rate
-33.5%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 3.7% |
| Return on equity | -29.3% |
| Net Margin | -26.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is HansBiomed (KOSDAQ:042520) A Risky Investment?
Feb 29
HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth
Feb 29Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?
Apr 10Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?
Mar 06HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.
Jan 30Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 08
Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?
Nov 20Revenue & Expenses BreakdownBeta
How HansBiomed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 78,321 | -20,480 | 41,559 | 5,178 |
| 30 Sep 23 | 78,032 | -23,045 | 40,623 | 5,597 |
| 30 Jun 23 | 78,561 | -9,067 | 37,736 | 6,151 |
| 31 Mar 23 | 80,309 | -9,183 | 38,500 | 6,111 |
| 31 Dec 22 | 76,991 | 3,937 | 37,465 | 6,098 |
| 30 Sep 22 | 74,459 | 6,147 | 36,067 | 5,658 |
| 30 Jun 22 | 68,200 | -10,348 | 37,210 | 5,860 |
| 31 Mar 22 | 63,498 | -11,639 | 35,703 | 6,482 |
| 31 Dec 21 | 58,284 | -22,373 | 36,431 | 6,934 |
| 30 Sep 21 | 59,098 | -18,289 | 38,077 | 7,148 |
| 30 Jun 21 | 70,297 | -25,593 | 44,366 | 6,797 |
| 31 Mar 21 | 73,649 | -23,626 | 43,018 | 6,040 |
| 31 Dec 20 | 80,678 | -16,686 | 40,937 | 5,621 |
| 30 Sep 20 | 80,098 | -17,840 | 37,995 | 5,511 |
| 30 Jun 20 | 72,293 | 5,259 | 26,497 | 5,462 |
| 31 Mar 20 | 71,395 | 7,539 | 25,453 | 5,098 |
| 31 Dec 19 | 69,043 | 9,867 | 23,920 | 4,703 |
| 30 Sep 19 | 66,991 | 9,951 | 22,332 | 4,038 |
| 30 Jun 19 | 64,768 | 5,521 | 21,983 | 3,170 |
| 31 Mar 19 | 61,501 | 5,253 | 19,831 | 2,526 |
| 31 Dec 18 | 56,945 | 4,508 | 17,793 | 1,497 |
| 30 Sep 18 | 51,746 | 4,159 | 14,812 | 1,147 |
| 30 Jun 18 | 46,866 | 6,757 | 10,532 | 920 |
| 31 Mar 18 | 42,297 | 5,623 | 8,598 | 850 |
| 31 Dec 17 | 39,977 | 6,150 | 7,566 | 645 |
| 30 Sep 17 | 39,058 | 7,828 | 7,492 | 777 |
| 30 Jun 17 | 37,269 | 6,660 | 8,113 | 330 |
| 31 Mar 17 | 34,611 | 6,756 | 7,761 | 284 |
| 31 Dec 16 | 32,296 | 6,373 | 7,599 | 398 |
| 30 Sep 16 | 29,048 | 4,625 | 6,971 | 177 |
| 30 Jun 16 | 27,494 | 4,911 | 6,702 | 361 |
| 31 Mar 16 | 26,337 | 5,364 | 6,031 | 323 |
| 31 Dec 15 | 24,118 | 4,856 | 5,406 | 326 |
| 30 Sep 15 | 23,428 | 4,909 | 4,969 | 369 |
| 30 Jun 15 | 23,005 | 4,271 | 5,057 | 536 |
| 31 Mar 15 | 22,726 | 3,878 | 5,230 | 533 |
| 31 Dec 14 | 21,451 | 3,621 | 5,076 | 524 |
| 30 Sep 14 | 21,033 | 3,498 | 4,995 | 513 |
| 30 Jun 14 | 21,124 | 4,116 | 4,490 | 191 |
| 31 Mar 14 | 20,623 | 3,710 | 4,117 | 178 |
| 31 Dec 13 | 21,099 | 4,209 | 4,054 | 182 |
| 30 Sep 13 | 20,066 | 3,441 | 4,140 | 143 |
Quality Earnings: A042520 is currently unprofitable.
Growing Profit Margin: A042520 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A042520 is unprofitable, and losses have increased over the past 5 years at a rate of 34.8% per year.
Accelerating Growth: Unable to compare A042520's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A042520 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A042520 has a negative Return on Equity (-29.28%), as it is currently unprofitable.